Latest Breaking News On - Prnewswire clarity pharmaceuticals - Page 1 : comparemela.com

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
sydneysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sydneysun.com Daily Mail and Mail on Sunday newspapers.

United statesNew south walesAlan taylorEd englJames webbTechnology platformAmerican cancer institutePrnewswire clarity pharmaceuticalsClarity pharmaceuticalsDrug administrationExecutive chairpersonMaximum intensityTargeted copper theranosticTargeted copper theranosticsMulticenter studyDiagnostic accuracy

First patient dosed in Clarity s registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Highlights

United statesNew south walesAlan taylorAlan taylor catherineLengyelova emmettPrnewswire clarity pharmaceuticalsAmerican cancer societyClarity pharmaceuticalsUrology cancer center xcancer omahaTechnology platformAmerican cancer instituteUrology cancer centerExecutive chairpersonEmission tomographyCancer statisticsMortality worldwide

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesAlan taylorLuke nordquistAmerican cancer societyAccess programDrug administrationClarity pharmaceuticalsUrology cancer center xcancerAmerican cancer institutePrnewswire clarity pharmaceuticalsProstate specific antigenResponse evaluation criteria in solid tumoursExpanded access programUrologic medical oncologistPrincipal investigator

Registrational Phase III CLARIFY trial in prostate cancer commences

/PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products.

United statesNew south walesAlan taylorClarity pharmaceuticalsPrnewswire clarity pharmaceuticalsDrug administrationTechnology platformAmerican cancer instituteUrology cancer center xcancer omahaUrology cancer centerExecutive chairperson

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
philippinetimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from philippinetimes.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesAlan taylorLuke nordquistClarity pharmaceuticalsPrnewswire clarity pharmaceuticalsUrology cancer center xcancer omahaAmerican cancer instituteAccess programDrug administrationAmerican cancer societyProstate specific antigenResponse evaluation criteria in solid tumoursExpanded access programUrologic medical oncologistPrincipal investigator